STAT October 28, 2024
The company, Ottimo Pharma, is pursuing one of the hottest approaches in immuno-oncology
LONDON — It hasn’t even been a year since Pfizer closed its $43 billion acquisition of Seagen — one of the biggest biopharma deals in years — but David Epstein, who was CEO of Seagen, is back.
Epstein...